GlaxoSmithKline Pakistan Limited

GLAXO

PK0001301016

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
100.1 ^PKR	+2.07%		-0.29%	+20.63%

Apr. 01	GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Glaxosmithkline Pakistan Limited Announces Board Changes

June 01, 2021 at 03:02 pm EDT

GlaxoSmithKline Pakistan Limited announced that Mr. Hasham Baber has been appointed as Executive Director of the company with effect from June 01, 2021 in place of Mr. Abdul Samad.

Latest news about GlaxoSmithKline Pakistan Limited

GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 31	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Glaxosmithkline Pakistan Limited Announces Change of Company Secretary	23-06-02	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
GlaxoSmithKline Pakistan Limited Announces Board Changes	22-11-10	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-01	CI
Glaxosmithkline Pakistan Limited Appoints Simon Forster as Director	22-09-28	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Glaxo Smith Kline Pakistan Limited Appoints Lai Kuen Goh as Director	22-08-11	CI
GlaxoSmithKline Pakistan Limited Announces Board Changes	22-08-10	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-01	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-03	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-25	CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-23	CI
Glaxosmithkline Pakistan Limited Announces Board Changes	21-06-01	CI
Glaxosmithkline Pakistan Limited Announces Executive Changes	21-06-01	CI
GlaxoSmithKline Pakistan Limited Approves Final Cash Dividend for the Year Ended December 31, 2020	21-03-10	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-10	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-28	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-24	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-15	CI
GlaxoSmithKline Pakistan Limited Announces Board Changes	20-04-02	CI
Glaxosmithkline Pakistan Limited Recommends Final Cash Dividend for the Year Ended Dec. 31, 2019	20-03-11	CI
Glaxosmithkline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-11	CI

Chart GlaxoSmithKline Pakistan Limited

Duration

Period

More charts

GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, including but not limited to psoriasis, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GLAXOSMITHKLINE PAKISTAN LIMITED	+20.63%	115M
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B